AMSBIO announce a new service designed to provide high-content cytometry data on cells and tissues enabling the automated analysis of fluorescent biomarkers on living cells or long-term stored biobanked cells and tissues.
Leveraging the innovative ChipCytometry platform, AMSBIO is able to offer a complete workflow solution (products and services) for high-content cytometry on cells and tissues, from sample preparation and biobanking to biomarker analysis and data mining.
The ChipCytometry platform operates by immobilizing cells in microfluidic chips, which are later stained with antibodies for multiplex biomarker detection. Using the ChipCytometry platform - AMSBIO can offer quantitative analysis of a virtually unlimited number of protein biomarkers in a single sample. AMSBIO is also to offer custom assays facilitating analysis of almost any antibody / biomarker target. Not only can this technology deliver quantitative biomarker analysis but it can also facilitate both pre- and post-treatment immune cell profiling – a key part of characterizing the complexities of cancer biology.
Using this novel microfluidics chip-based approach - AMSBIO can offer stable sample storage and re-interrogation for up to 2 years. Beneficially the ChipCytometry platform offers industry-leading resolution enabling production of the highest quality data. All customers using this service receive a detailed analysis report as well as the full .fcs raw data file.
For further information please visit www.amsbio.com/cytometry-service/ or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / email@example.com.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.
Dr Bill Bradbury